

# **US - OSHA SAFETY DATA SHEET**

Issue Date 15-Apr-2015 . Revision Date 30-Jul-2019 Version 5

# 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

**Product identifier** 

Product Name Diphtheria and Tetanus Toxoids Adsorbed

Other means of identification

**Product Information** Single-dose vial in package of 10 vials.

Synonyms Diphtheria and Tetanus Toxoids Adsorbed Suspension for Intramuscular Injection

Recommended use of the chemical and restrictions on use

**Recommended Use** Active immunization against diphtheria and tetanus.

Uses advised against Not available.

Details of the supplier of the safety data sheet

Supplier Address Sanofi Pasteur Discovery Drive Swiftwater, PA 18370

Phone: 1-800-VACCINE (1-800-822-2463)

**Emergency telephone number** 

**24 Hour Emergency Phone** 1-703-741-5970 / 1-800-424-9300 CCN # 2118 (CHEMTREC)

# 2. HAZARDS IDENTIFICATION

### Classification

#### **Health Hazards**

Not classified.

#### Physical hazards

Not classified.

# **OSHA Regulatory Status**

This product is a vaccine that is safe for consumers when used according to the label directions. Potential hazards that may occur if product is not used according to the consumer label are as follows throughout the sheet.

#### Label elements

## **Emergency Overview**

Normal precautions common to safe manufacturing practice should be followed in handling and storage.

Appearance Cloudy, white suspension Physical state Liquid Odor Not available.

# **Hazards not otherwise classified (HNOC)**

Not classified as a hazardous substance.

·

# 3. COMPOSITION/INFORMATION ON INGREDIENTS

#### **Synonyms**

Diphtheria and Tetanus Toxoids Adsorbed Suspension for Intramuscular Injection

Revision Date 30-Jul-2019

Chemical Name	CAS No.	Weight-%
Diphtheria Toxoid Adsorbed	N/A	N/A
Tetanus Toxoid Adsorbed	N/A	N/A
Isotonic sodium chloride solution	7647-14-5	q.s. to 100

Note: Ingredients below reportable levels are not listed.

## 4. FIRST AID MEASURES

First aid measures

Eye contact In case of eye contact, immediately flush eyes with fresh water for at least 15 minutes while

holding the eyelids open. Remove contact lenses if worn. Get medical attention if irritation

persists.

**Skin Contact** In case of contact, remove contaminated clothing. Immediately flush skin with copious

amounts of water for at least 15 minutes. Obtain medical attention if skin reaction occurs.

In case of inhalation, remove to fresh air. If breathing is difficult, administer oxygen. Seek

medical attention immediately.

Ingestion In case of accidental ingestion, wash out mouth with copious amounts of water. Seek medical

attention if needed. Do not induce vomiting unless directed by medical personnel. Never give

anything by mouth to an unconscious person.

Self-protection of the first aider Do not use mouth-to-mouth method if victim ingested or inhaled the substance; give artificial

respiration with the aid of a pocket mask equipped with a one-way valve or other proper

respiratory medical device.

Most important symptoms and effects, both acute and delayed

Symptoms Common effects of the vaccine include the following: pain, redness, and hardness of the

injection site; crying; fever; loss of appetite.

Indication of any immediate medical attention and special treatment needed

# 5. FIRE-FIGHTING MEASURES

#### Suitable extinguishing media

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media None known.

#### Specific hazards arising from the chemical

Not available.

Hazardous combustion products Not available.

Explosion data

Sensitivity to Mechanical Impact Not available. Sensitivity to Static Discharge None known.

#### Protective equipment and precautions for firefighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective

·

Revision Date 30-Jul-2019

gear.

### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

Personal precautions Wear appropriate personal protective equipment (see Section 8).

**Environmental precautions** 

**Environmental precautions** See Section 12 for additional ecological information.

Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Wipe up with absorbent material (e.g. cloth) for disposal. Area where spill occurred can be

cleaned with the regular cleaning materials designated for the area.

7. HANDLING AND STORAGE

Precautions for safe handling

Advice on safe handling Handle in accordance with good industrial hygiene and safety practice.

Conditions for safe storage, including any incompatibilities

Storage Conditions Store at 2° to 8°C (35° to 46°F). Do not freeze.

Incompatible materials Not available.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

**Control parameters** 

Exposure Guidelines This product, as supplied, does not contain any hazardous materials with Occupational

Exposure Limits (OEL) established by the region specific regulatory bodies.

**Appropriate engineering controls** 

Engineering Controls

Used as supplied, no special engineering controls are needed when administering the

vaccine.

Individual protection measures, such as personal protective equipment

**Eye/face protection** In laboratory or industrial settings, safety glasses with side shields are recommended.

**Skin and body protection** In laboratory or industrial settings, gloves and lab coats are recommended.

Respiratory protection Used as supplied, general room ventilation is acceptable and no special respiratory

protection is needed when administering the vaccine.

**General Hygiene Considerations** Always observe good personal hygiene measures, such as washing after handling the

material and before eating, drinking, and/or smoking. Routinely wash work clothing and

protective equipment.

9. PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Physical state Liquid

AppearanceCloudy, white suspensionOdorNot available.ColorWhiteOdor thresholdNot available.

Property Values Remarks • Method

pH Not available.

Melting point/freezing point Not available.

Boiling point / boiling range Not available.

Flash point Not available.
Evaporation rate Not available.
Flammability (solid, gas) Not available.

Flammability Limit in Air

**Upper flammability limit:** Not available. Lower flammability limit: Not available. Vapor pressure Not available. Vapor density Not available. **Specific Gravity** Not available. Water solubility Not available. Solubility in other solvents Not available. Partition coefficient Not available. **Autoignition temperature** Not available. **Decomposition temperature** Not available. Kinematic viscosity Not available. Dynamic viscosity Not available. **Explosive properties** Not available. Oxidizing properties Not available.

**Other Information** 

Softening point
Molecular weight
VOC Content (%)
Density
Not available.
Not available.
Not available.
Not available.
Not available.
Not available.

### 10. STABILITY AND REACTIVITY

### Reactivity

Not reactive under normal conditions.

### **Chemical stability**

Stable under normal conditions.

### **Possibility of Hazardous Reactions**

None under normal handling.

**Hazardous polymerization** Hazardous polymerization does not occur.

#### Conditions to avoid

Not available.

### Incompatible materials

Not available.

### **Hazardous Decomposition Products**

None under normal use conditions.

# 11. TOXICOLOGICAL INFORMATION

# Information on likely routes of exposure

Product Information No data available.

**Inhalation** No impact known or expected under normal use.

**Eye contact** No impact known or expected under normal use.

**Skin Contact** No impact known or expected under normal use.

**Ingestion** No impact known or expected under normal use.

### **Acute Effects**

Chemical Name	Oral LD50	Dermal LD50	Inhalation LC50	Intravenous LD50
Isotonic sodium chloride solution	= 3 g/kg (Rat)	> 10 g/kg (Rabbit)	> 42 g/m <sup>3</sup> (Rat) 1 h	-
7647-14-5				

#### Information on toxicological effects

**Symptoms** 

Common effects of the vaccine include the following: pain, redness, and hardness of the injection site; crying; fever; loss of appetite.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Skin corrosion/irritation Not available. Serious eye damage/eye irritation Not available. Not available. Irritation Corrosivity Not available. Sensitization Not available.

Germ cell mutagenicity Diphtheria and Tetanus Toxoids Adsorbed has not been evaluated for mutagenic potential. Carcinogenicity Diphtheria and Tetanus Toxoids Adsorbed has not been evaluated for carcinogenicity

potential.

Reproductive toxicity Diphtheria and Tetanus Toxoids Adsorbed is not approved for use in individuals 7 years of

age and older. Human or animal data are not available to assess vaccine-associated risks in pregnancy or on milk production, its presence in breast milk, or its effects on the breastfed

infant.

**Developmental Toxicity** Not available. Not available. **Teratogenicity** STOT - single exposure Not classified. STOT - repeated exposure Not classified. Chronic toxicity Not available. **Subchronic toxicity** Not available. **Target Organ Effects** Not available. **Neurological effects** Not available. Other adverse effects Not available. **Aspiration hazard** Not available.

# 12. ECOLOGICAL INFORMATION

#### **Ecotoxicity**

Chemical Name	Algae/aquatic plants	Fish	Toxicity to	Crustacea
			microorganisms	
Isotonic sodium chloride	-	5560 - 6080: 96 h Lepomis	_	1000: 48 h Daphnia magna
solution		macrochirus mg/L LC50		mg/L EC50 340.7 - 469.2: 48
7647-14-5		flow-through 12946: 96 h		h Daphnia magna mg/L EC50
		Lepomis macrochirus mg/L		Static
		LC50 static 6020 - 7070: 96 h		
		Pimephales promelas mg/L		
		LC50 static 7050: 96 h		
		Pimephales promelas mg/L		
		LC50 semi-static 6420 -		
		6700: 96 h Pimephales		
		promelas mg/L LC50 static		
		4747 - 7824: 96 h		
		Oncorhynchus mykiss mg/L		
		LC50 flow-through		

# Persistence and degradability

Not available.

#### Bioaccumulation

Not available.

**Mobility** 

Not available.

Other adverse effects Not available.

# 13. DISPOSAL CONSIDERATIONS

Waste treatment methods

Disposal of wastes

Disposal should be in accordance with applicable regional, national and local laws and

regulations.

Contaminated packaging Disposal should be in accordance with applicable regional, national and local laws and

regulations.

US EPA Waste Number Not applicable.

California Hazardous Waste Codes Not applicable.

# 14. TRANSPORT INFORMATION

**DOT** Not regulated.

TDG Not regulated.

MEX Not regulated.

ICAO (air) Not regulated.

IATA Not regulated.

**IMDG** Not regulated.

RID Not regulated.

ADR Not regulated.

ADN Not regulated.

# 15. REGULATORY INFORMATION

# **US Federal Regulations**

#### **SARA 313**

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.

# SARA 311/312 Hazard Categories

Acute health hazardNoChronic Health HazardNoFire hazardNoSudden release of pressure hazardNoReactive HazardNo

# **CWA (Clean Water Act)**

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

### **CERCLA**

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355).

# **US State Regulations**

# **California Proposition 65**

Component (Formaldehyde) is on Proposition 65 list; however, based on percentage of formulation it is not considered hazardous.

#### U.S. State Right-to-Know Regulations

This drug is regulated by the Food and Drug Administration and is therefore exempt from State Right-to-Know Regulations.

# **16. OTHER INFORMATION**

**Prepared By IES Engineers** Issue Date 15-Apr-2015 **Revision Date** 30-Jul-2019

**Revision Note** Updated Section 11: Reproductive Toxicity; revised by Sanofi Pasteur

#### **Disclaimer**

Sanofi Pasteur considers that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. The information contained herein is designated only as guidance for safe handling, storage and use of the substance and is not a specification nor does it guarantee any specific properties. Only competent personnel, within a controlled environment should handle all chemicals. Sanofi Pasteur cannot be held liable for any loss, injury or damage from contact with the product.

**End of Safety Data Sheet**